MHRA Class 4 Medicines Defect Notification: Tuzulby prolonged-release chewable tablets (Neuraxpharm UK Ltd)
MHRA Class 4 Medicines Defect Notification: Tuzulby prolonged-release chewable tablets (Neuraxpharm UK Ltd) Drug alert number: EL(26)A/36 Date issued: 23 July 2026 Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged release 20mg, 30mg and [...]
The post MHRA Class 4 Medicines Defect Notification: Tuzulby prolonged-release chewable tablets (Neuraxpharm UK Ltd) appeared first on Community Pharmacy England.
Important: This alert is aggregated automatically for information only.
Always refer to the original source and follow your practice's own clinical governance procedures.
Get the weekly digest — all new alerts summarised and delivered to your NHS inbox every Monday.
View this week's digest